BioVie Inc. (BIVIW) Analyse boursière

Présentation de l'entreprise

BioVie Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development of therapeutic interventions for neurological, neurodegenerative disorders, and advanced liver disease within the United States market. The company focuses its research and development efforts on BIV201, a specific drug candidate currently undergoing phase 2 clinical trials for the management of ascites associated with chronic liver cirrhosis. Although the specific sector and industry classifications are not explicitly defined in the available data, the operational scope places the firm squarely within the biotechnology and pharmaceutical development landscape, a sector characterized by high capital expenditure and significant regulatory hurdles. The company's scale is defined by a market capitalization that is not currently quantified in the provided financial statements, an annual revenue stream that remains unreported in the trailing twelve months, and a workforce comprising 13 employees. These figures indicate that BioVie Inc. functions as a micro-cap or pre-revenue entity typical of early-stage biopharmaceutical companies, where value is derived primarily from intellectual property pipelines rather than current commercial sales or extensive operational infrastructure.

Santé financière

In the trailing twelve months, the company reported a net income of -$17,478,136 and an EBITDA of -$17,968,812, while revenue figures for the same period are not disclosed in the available data. The substantial negative gap between reported revenue and net income, in the absence of revenue data, highlights a cost structure dominated by research and development expenses, which is standard for clinical-stage companies but necessitates careful monitoring of burn rates. Free cash flow stands at -$8,277,755, indicating that the company is currently consuming cash reserves to fund its operations and clinical trials, which limits immediate financial flexibility until product approvals or commercialization milestones are achieved. The gross margin, operating margin, and profit margin are all recorded at 0.0%, reflecting that the company has not yet generated commercial revenue sufficient to calculate meaningful profitability metrics at this stage of development. On the liability side, the company holds $20.54 million in cash against $314,915 in debt, resulting in a debt-to-equity ratio of 1.64, which suggests a leveraged balance sheet relative to equity but maintains significant cash liquidity to cover obligations. The current ratio is reported at 7.25, a figure that indicates a very strong short-term liquidity position, suggesting the company possesses ample current assets to meet its short-term liabilities despite the ongoing cash burn from operations. Return on equity is -80.7% and return on assets is -47.2%, metrics that reveal that the company is currently destroying shareholder value and utilizing assets inefficiently in a traditional profitability sense, which is expected for firms in the development phase before generating positive cash flows.

Évaluation de la valorisation

The trailing twelve-month P/E ratio and forward P/E ratio are both listed as N/A, implying that the lack of positive earnings makes traditional earnings-based valuation multiples inapplicable and suggesting that future earnings trajectories are highly uncertain until clinical success is demonstrated. The price-to-book ratio is 0.07, a metric that indicates the company's market valuation is trading at a fraction of its book value, which often signals that the market prices the firm conservatively or that the asset base is not fully reflected in the market capitalization due to the intangible nature of its drug pipeline. Since revenue is not available, the price-to-sales ratio and EV/EBITDA are also N/A, meaning that alternative valuation metrics that rely on sales or earnings multiples cannot be applied to assess the company's intrinsic value at this time. The stock has a 52-week high of $0.28 and a 52-week low of $0.17; without a specific current price in the provided facts, the trading position relative to this range can only be described as fluctuating within a narrow band of 11 cents, which is typical for low-priced biotech stocks subject to high volatility. The beta coefficient is 0.56, which indicates that the stock's price volatility is approximately 44% lower than the broader market, suggesting lower systematic risk relative to the overall equity market despite the inherent risks associated with clinical-stage development.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of earnings growth rates against revenue expansion, though the negative net income confirms that earnings are not growing in a positive direction. As a non-dividend payer, the company has a dividend yield and payout ratio of N/A, indicating that all available cash and potential future earnings are being reinvested into the company's growth initiatives, clinical trials, and operational expansion rather than being distributed to shareholders. The overall growth and income profile for BioVie Inc. is currently defined by a focus on capital preservation and pipeline advancement rather than income generation or revenue expansion, as evidenced by the negative financial performance and lack of commercial sales data.